When Does Dupixent Go Generic?

Dupixent is a biologic, so it will not face a traditional "generic." Instead, biosimilar developers file under the FDA's Biologics Price Competition and Innovation Act (BPCIA) pathway and must complete analytical, clinical, and immunogenicity studies to prove no meaningful difference from the reference product. Biosimilar entry is slower and price erosion is gentler than small-molecule generics — discounts of 15–40% are typical rather than the 80%+ collapse seen with pill generics. The BPCIA "patent dance" lets the brand holder assert its portfolio patents serially, which is why a single late-expiring formulation or manufacturing patent (this portfolio runs to 2042) can push real biosimilar availability years past the first composition expiry.

Because Dupixent's patent cliff is within three years, generic manufacturers are likely already preparing ANDA filings or have filed Paragraph IV certifications. Under Hatch-Waxman, the first successful Paragraph IV challenger earns a 180-day exclusivity period as the sole generic. Watch FDA's Paragraph IV certification list for filing activity tied to Dupixent.

When the first Dupixent biosimilar launches, expect list-price discounts of roughly 15–40% rather than the steep collapse seen with small-molecule generics. Biosimilars require their own manufacturing and clinical investment, and many payers keep the reference biologic on formulary, so competition builds gradually as additional biosimilars are approved.

The authoritative source for which generic versions are actually approved is the FDA Orange Book, which lists every ANDA-approved equivalent and the patents an applicant had to clear. To compare cash prices once a generic lands, check GoodRx and Mark Cuban's Cost Plus Drugs. Underlying patent expiration data on this page is sourced from USPTO PatentsView.

Dupixent is protected by 18 US patents — a large portfolio that signals an aggressive lifecycle management strategy. Mega-portfolios of 15+ patents are characteristic of top-selling drugs (Humira famously had over 130) where the manufacturer has built layered protection across composition, multiple formulations, dosing schedules, drug-device combinations, and method-of-use claims for individual indications. These layered portfolios typically face Paragraph IV litigation under the Hatch-Waxman framework as generic challengers test secondary patents one by one.

Dupixent patent rights are held across 2 entities: Regeneron Pharmaceuticals Inc., Sanofi. Multi-assignee portfolios usually reflect co-development partnerships, licensing splits between an originator and a marketing partner, or assignments made during corporate restructurings. Multi-party ownership can complicate generic entry — a challenger may need to clear patents from each holder separately, and settlements are harder to reach.

The Dupixent portfolio scores 72/100 (Grade B, "strong") on the PatentCliff Strength index. The strongest signal is portfolio size (100/100), and the weakest is technology diversity (37/100). The four factors are weighted by how well they predict real-world resilience to generic challenge: portfolio size 30%, claims breadth 25%, time remaining 25%, and technology diversity 20%.

Looking at the 18 dated patents in the portfolio, the largest cluster (8 patents) falls in the "5–10 years (2032–2036)" bucket. That distribution matters because generic entry is gated by the latest unexpired blocking patent, not the earliest — even one late-expiring formulation patent can delay biosimilar launch by years if it survives a Paragraph IV challenge.

The 20-year patent term in the United States runs from the earliest non-provisional filing date, not the grant date. That means a patent granted in 2015 from a 2010 filing has only 15 years of life left at grant — a feature of US patent law that creates the layered "cliff" pattern visible in most branded drug portfolios. Patent Term Extension under 35 USC § 156 can add up to 5 years for time lost to FDA review, and pediatric exclusivity can add 6 months on top.